Next Article in Journal
Thymoquinone Potentiates the Effect of Phenytoin against Electroshock-Induced Convulsions in Rats by Reducing the Hyperactivation of m-TOR Pathway and Neuroinflammation: Evidence from In Vivo, In Vitro and Computational Studies
Next Article in Special Issue
An Update on the Anticancer Activity of Xanthone Derivatives: A Review
Previous Article in Journal
The Antibacterial Synthetic Flavonoid BrCl-Flav Exhibits Important Anti-Candida Activity by Damaging Cell Membrane Integrity
Previous Article in Special Issue
Investigation of the Mechanisms of Cytotoxic Activity of 1,3-Disubstituted Thiourea Derivatives
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 14
Issue 11
10.3390/ph14111131
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones

by
Marta Gargantilla
1,
José López-Fernández
1,
Maria-Jose Camarasa
1,
Leentje Persoons
2,
Dirk Daelemans
2,
Eva-Maria Priego
1,* and
María-Jesús Pérez-Pérez
1,*
1
Instituto de Química Médica (IQM, CSIC) c/Juan de la Cierva 3, 28006 Madrid, Spain
2
KU Leuven Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2021, 14(11), 1131; https://doi.org/10.3390/ph14111131
Submission received: 13 October 2021 / Revised: 2 November 2021 / Accepted: 4 November 2021 / Published: 6 November 2021
(This article belongs to the Special Issue Anticancer Drugs 2021)
Browse Figures
Versions Notes

Abstract

:
The nuclear export receptor exportin-1 (XPO1, CRM1) mediates the nuclear export of proteins that contain a leucine-rich nuclear export signal (NES) towards the cytoplasm. XPO1 is considered a relevant target in different human diseases, particularly in hematological malignancies, tumor resistance, inflammation, neurodegeneration and viral infections. Thus, its pharmacological inhibition is of significant therapeutic interest. The best inhibitors described so far (leptomycin B and SINE compounds) interact with XPO1 through a covalent interaction with Cys528 located in the NES-binding cleft of XPO1. Based on the well-established feature of chalcone derivatives to react with thiol groups via hetero-Michael addition reactions, we have synthesized two series of chalcones. Their capacity to react with thiol groups was tested by incubation with GSH to afford the hetero-Michael adducts that evolved backwards to the initial chalcone through a retro-Michael reaction, supporting that the covalent interaction with thiols could be reversible. The chalcone derivatives were evaluated in antiproliferative assays against a panel of cancer cell lines and as XPO1 inhibitors, and a good correlation was observed with the results obtained in both assays. Moreover, no inhibition of the cargo export was observed when the two prototype chalcones 9 and 10 were tested against a XPO1-mutated Jurkat cell line (XPO1C528S), highlighting the importance of the Cys at the NES-binding cleft for inhibition. Finally, their interaction at the molecular level at the NES-binding cleft was studied by applying the computational tool CovDock.

Graphical Abstract

1. Introduction

Exportin-1 (XPO1, also known as chromosome region maintenance 1, CRM1) is the best-characterized nuclear transporter that mediates the traffic of high molecular weight molecules (i.e., proteins or RNA) from the nucleus to the cytoplasm [1,2]. Aberrant XPO1 function is implicated in different diseases, including different types of cancers, inflammation, neurodegeneration and viral infections [3,4,5,6,7,8]. In the nucleus, exportin-1 recognizes specific leucine-rich peptide stretches, known as nuclear export signals (NES) in cargo proteins, and forms a ternary complex with RanGTP. When this exportin-RanGTP-cargo complex reaches the cytoplasm, GTP is hydrolyzed to GDP, disrupting the ternary complex and releasing the cargo [2].
XPO1 has been found to be overexpressed in a variety of solid tumors and hematologic cancers, and in many cases, elevated XPO1 levels have been correlated to poor prognosis [7,9]. Pharmacological inhibition of XPO1 has been considered an appealing anticancer strategy [2,4,5,10]. Indeed, XPO1 cargo proteins include many tumor suppressors and cell growth regulators, such as p53, Topo2, FOXOs, etc., [7,8], and XPO1 inhibition has been shown to restore nuclear localization and function of these tumor suppressors, leading to apoptosis of the cancer cells [11].
The most potent XPO1 inhibitors described, either from natural or synthetic origin, are α,β-unsaturated carbonyl compounds that bind into the NES-binding cleft of XPO1 through covalent interactions with Cys528 [2,4,10,12,13]. These inhibitors prevent the interaction of cargo proteins with XPO1 and, hence, block cargo export to the cytoplasm [14]. Only recently, a non-covalent XPO1 inhibitor has been described [15], while a first report on allosteric inhibitors with moderate affinity has been published [16].
The first XPO1 inhibitor clinically tested was the natural product leptomycin B (1, Figure 1). However, clinical trials were discontinued due to severe cytotoxicity [17], probably associated with irreversible inhibition. Among synthetic compounds, the N-azolylacrylate compounds [12,13], also known as selective inhibitors of nuclear export (SINE) exemplified by KPT-330 (selinexor) (2), KPT-185 (3) or the second generation compound KPT-8602 (eltanexor) (4) (Figure 1), have been described as very slowly reversible inhibitors [12,18,19,20]. Indeed, the recent FDA approval of selinexor (KPT-330, XPOVIO, 2) for the treatment of patients with heavily pretreated relapsed or refractory multiple myeloma and diffuse B cell lymphoma supports the significance of XPO1 as a target in hematological malignancies [21]. Other interesting XPO1 inhibitors are the 1-(pyridin-2-ylamino)-1H-pyrrole-2,5-dione derivatives S109 (5) and CBS9106 (6) [22,23], with the latter being evaluated in Phase 1 clinical trials [24].
The overall structure of XPO1 complexed with Ran and RanBP1 is shown in Figure 2A, where the NES-binding cleft is colored in grey. Structurally, this cleft contains five hydrophobic pockets (named Φ0–Φ4, Figure 2B) that lodge the hydrophobic key residues of the cargo protein. Cys528 (which corresponds to Cys539 in Saccharomyces cerevisiae in the X-ray structure) is located between the Φ3 and Φ4 pockets. While leptomycin B occupies almost all Φ pockets [17], the KPT compounds exemplified by KPT-8602 (Figure 2C) only occupy a small part of the NES-binding cleft [25], demonstrating that XPO1 inhibition can be accomplished by only occupying part of the hydrophobic cleft. By analysing the binding mode of KPT-8602, it can be concluded that an aromatic hydrophobic core is located below the Cys-reactive residue, while more polar substituents (a pyrimidinyl ring in KPT-8602) can be lodged over the Cys in the proximities of the Φ4 pocket.
Based on these precedents, we envisioned the chalcone scaffold as a suitable α,β-unsaturated carbonyl construct for XPO1 inhibition by interaction with Cys528 based on their ability to behave as Michael acceptors. Indeed, quite similar α,β-unsaturated carbonyl compounds such as caffeic acid phenylethyl ester (7, Figure 1) or curcumin (8) have been described as XPO1 inhibitors. Moreover, since chalcones can undergo a retro-Michael reaction, the expected inhibition should be reversible. Reversible covalent inhibitors may have some advantages versus their irreversible counterparts, such as the possibility to tune the residence time and/or to avoid the irreversible inhibition of off-targets [26], while as a disadvantage they may show lower potency. Compounds 9 and 10 (Figure 3) were proposed as prototypes, so that ring A should be lodged below the Cys where the covalent interaction takes place, while the pyrimidine (ring B) should be located closer to the Φ4 pocket. The XPO1 inhibition obtained with these compounds triggered us to explore closely related structural analogues (Figure 3). Thus, their synthesis, antiproliferative activity against a panel of cancer cell lines, XPO1 inhibition and docking studies at the NES-binding cleft of XPO1 are here described.

2. Results and Discussion

2.1. Synthesis

It has been described by performing kinetic measurements in α-X-2′3,4,4’-tetramethylchalcones that the nature of the substituent at position α of the chalcone affects their reactivity as electrophiles versus thiol groups [27]. In such series, the α-COOEt substituent led to a similar reactivity as that of the α-H chalcone; the α-CH3 chalcone was poorly electrophilic, while the α-CN chalcone was the most electrophilic. Thus, in the naphthyl series (Figure 3), the synthesis of the chalcones where R1 = H, COOCH3, CH3 or CN was accomplished. The reaction of 1-(naphthalen-2-yl)ethan-1-one (11) with pyrimidine-5-carbaldehyde in the presence of Ba(OH)2 afforded α-H chalcone 9 in a 55% yield (Scheme 1). The ketone 11 reacted with dimethyl carbonate, as described, to provide the methyl 3-oxopropanoate 12 [28], whose reaction with pyrimidine-5-carbaldehyde resulted in the α-COOCH3 chalcone 13. Reaction of the ester 12 with NH3/dioxane at 110 °C [29] led to the amide 14 that was further transformed into the chalcone 15. On the other hand, reaction of naphthalene 16 with propionyl chloride under Friedel–Crafts acylation conditions, as described [30], provided the 2-acyl derivative 17, together with a small proportion of its 1-isomer [31]. This mixture of isomers reacted with pyrimidine-5-carbaldehyde to yield the α-CH3 chalcone 18 (30%). Finally, the synthesis of the α-CN derivative was addressed by the reaction of 2-methylnaphthoate (19) with acetonitrile to provide 3-oxopropanenitrile 20 [32], which was further transformed into the α-CN chalcone 21. Compound 21 proved to be very unstable and readily decomposed in phosphate-buffered solution (PBS), hampering its biological evaluation.
A second set of modifications involved the incorporation as ring B of different pyridines instead of the 5-pyrimidinyl of the prototype 9. To this end, the ketone 11 was reacted with different aldehydes (21–23) in the presence of Ba(OH)2, using a mixture of methanol and water at rt, to yield the chalcones 24–26 (Scheme 2).
In parallel, we synthesized the 3,5-dimethoxyphenyl chalcone 10 (Scheme 3) by reaction of the 1-(3,5-dihydroxyphenyl)ethan-1-one 27 with methyl iodide to provide the ketone 28 [33], whose reaction with pyrimidine-5-carbaldehyde afforded the chalcone 10 (64% yield). Additionally, in this case, the α-COOCH3 chalcone was synthesized through the transformation of the ketone 28 into the methylpropionate 29 [34], and further reaction of this methyl ester with pyrimidine-5-carbaldehyde afforded the α-COOCH3 chalcone 30. On the other hand, as will be later shown in the molecular modeling studies, one of the methoxy groups of the chalcone 10 seems to be pointing towards the lower part of the NES-binding cleft that lodges the aliphatic chain of leptomycin B. Thus, one of the methoxy groups in the chalcone 10 was replaced by either a 2-methoxyethoxy or a 3,3-dimethylallyloxy group. To this end, the 3,5-dihydroxyacetophenone 27 was transformed in 2 steps into the corresponding ketones 31 and 32, whose reaction with pyrimidine-5-carbaldehyde afforded the chalcones 33 and 34 in a 32% and 41% yield, respectively.
For the α-H chalcones (9, 10, 24–26, 33, 34), the configuration of the double bond was easily assigned as E, as expected, based on the JH2-H3 value (15–16 Hz) in their 1H-NMR spectra [36]. The configuration of the α-substituted chalcones (13, 15, 18, 21, 30) was also assigned as E, based on previous reports [37,38].

2.2. Incubation with GSH

In order to determine if these chalcones could react with thiol groups through a hetero-Michael addition reaction, a few selected compounds (9, 10, 13 and 18) were incubated with glutathione (GSH). After different incubation times, the reactions were quenched by adding 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB, Ellman´s reagent) [39,40] (1:1 ratio with respect to the initial concentration of GSH). The course of the reaction was followed by HPLC, adapting reported procedures [41,42]. The prototype α-H chalcones 9 and 10 quickly reacted with GSH to provide the Michael addition products, as shown by HPLC-MS. These adducts underwent a retro-Michael addition reaction, generating the parent chalcone, demonstrating the reversibility of the reaction (see Figures S1 and S2). The α-COOCH3 chalcone 13 also provided the Michael adducts with GSH after a short reaction time, while longer incubations revealed that the adducts reverted to the parent chalcone (Figure S3). However, under the same incubation conditions with GSH, the α-CH3 chalcone 18 remained almost unaltered even after 4 h of incubation, and only a very small proportion of the addition products was detected (Figure S4). As already mentioned, the α-CN chalcone 21 could not even be tested due to instability in PBS, suggesting a very high electrophilic character. Thus, although this assay is only qualitative, the tendency observed among these chalcones nicely fits the reactivity described for α-X-2´3,4,4´-tetramethylchalcones [27].

2.3. Biological Results

2.3.1. Antiproliferative Activity

The synthesized compounds were tested for their antiproliferative activity against a panel of cancer cell lines using KPT-330 as a reference compound (Table 1).
The two prototype compounds 9 and 10 inhibited proliferation against all cell lines tested at single digit µM IC50 values, being between 5- to 30-fold less potent than the reference compound KPT-330. The α-substituted chalcones in the naphthyl series with an ester (compound 13) or methyl (compound 18) group were almost inactive in the proliferation assays, while the α-CONH2 chalcone 15 was slightly less active than the parent chalcone 9. When the 5-pyrimidinyl ring in 9 was replaced by different pyridines (pyridin-3-yl in 24, pyridin-2-yl in 25 or pyridin-4-yl in 26), the IC50 vales were maintained in the low µM range. Concerning the phenyl series, the α-COOCH3 chalcone 30 was considerably less active than the α-H chalcone 10. Moreover, replacement of one of the methoxy groups in compound 10 by longer ethers was compatible with antiproliferative activity, although up to a 20-fold increase in IC50 values was obtained for certain cell lines.

2.3.2. XPO1 Inhibition Studies

In order to determine if the observed antiproliferative activity was caused by XPO1 inhibition, the compounds were assayed in a reporter cell line based on the subcellular localization of a XPO1-dependent GFP reporter cargo protein [13]. Inhibition of XPO1-mediated nuclear export of the reporter is evident by its nuclear accumulation, which can be visualized and quantified compared to the untreated control, where the GFP protein localizes in the cytoplasm. Using this reporter cell line, the capacity of the synthesized chalcones to inhibit XPO1-mediated nuclear export was determined (Table 2).
The prototype chalcones 9 and 10 both in the naphthyl and phenyl series showed significant XPO1 inhibition, with IC50 values of 2.5 and 0.55 µM, respectively. Interestingly, among the naphthyl series, the chalcones substituted with an ester or a methyl group at the α-position of the double bond (compounds 13 and 18, respectively) that were inactive in the antiproliferative activity assays, were also inactive against XPO1. On the other hand, the α-CONH2 chalcone 15 or compounds with a pyridinyl ring (24–26) instead of the pyrimidinyl of the prototype 9, which had shown significant antiproliferative activity, inhibited XPO1 with IC50 values around or below 10 µM. Among the phenyl series, the α-COOCH3 derivative 30 was almost inactive against XPO1, while the extended ethers 33 and 34 were active, particularly the 3,3-dimethylallyl derivative 34, with an IC50 value of 1.59 µM.
Once XPO1 inhibition was confirmed, an additional experiment was performed for compounds 9 and 10 employing a Jurkat leukemia cell line where the cysteine residue at position 528 of XPO1 had been replaced by a serine residue (Jurkat XPO1C528S) [19,43]. The effect of the mutation on the activity of the inhibitors was assessed by the visualization of the subcellular localization of the XPO1 cargo RanBP1. As shown in Figure 4A (control experiment), in both wild-type and mutant Jurkat cells, RanBP1 is localized in the cytoplasm as a consequence of the correct nuclear export mediated by XPO1. When both cell lines were treated with KPT-330 at 1 μM (used as a positive control, Figure 4B), in the wild-type cell line, RanBP1 was accumulated in the nucleus, since KPT-330 blocked its binding to XPO1, whereas in the mutant cell line, KPT-330 was unable to interact with XPO1; therefore, RanBP1 remained in the cytoplasm. Similarly, when both cell lines were treated with our prototype compounds 9 and 10 at 4 μM (Figure 4C, D, respectively), RanBP1 accumulated in the nucleus in the case of the wild-type cells, whereas its nuclear export was not inhibited in the mutant cell line.
The IC50 values of compounds 9 and 10 regarding their XPO1 inhibitory activity in WT and C528S Jurkat cell lines are shown in Table 3. Both compounds 9 and 10 inhibited nuclear export of RanBP1 cargo protein with IC50 values of 2.2 and 0.3 μM, respectively, in the WT Jurkat cell line. These results were in agreement with the IC50 values obtained for XPO1 inhibition in the HeLa reporter cell line (Table 2), where the chalcone 10 was the most potent of the two. What is most relevant is that both compounds lost their inhibitory activity against the Jurkat XPO1C528S cell line, similar to the positive control KPT-330. Thus, these experiments evidenced the importance of Cys528 for the XPO1 inhibitory activity of these chalcones.
Thus, compounds 9 and 10, able to react with GSH in incubation studies, were among the most potent XPO1 inhibitors and also showed good antiproliferative activity. On the other hand, the α-CH3 chalcone 18, which poorly reacted with GSH in the incubation assays, was unable to inhibit XPO1 and also did not show antiproliferative activity. The most puzzling data comes from the esters 13 and 30, which were almost inactive against XPO1 and in antiproliferation assays. However, in the incubation studies with GSH, compound 13 seems to be as reactive as the α-H chalcone 9. Certainly, many factors can be involved in the lack of activity of this chalcone. A potential explanation may arise by taking into account that the XPO1 inhibition assays are performed in a cell culture, so that the presence of esterases might convert the ester into the corresponding carboxylic acid. If this is the case, the resulting α-COOH chalcone would be very poorly electrophilic based on the reactivity described for α-X-2´3,4,4´-tetramethylchalcones [27], and thus, its capacity to behave as a Michael acceptor against XPO1 would be seriously compromised.

2.4. Docking Studies

Docking molecular studies have been carried out for compounds 9 and 10 with CovDock [44,45], a computational tool developed by Schrödinger to perform covalent docking, using the coordinates of the S. cerevisiae XPO1 protein in its complex with KPT-8602 [20]. Using this tool, a covalent bond is created between the SH of Cys539 (Cys528 in human XPO1) in the NES-binding cleft and the β-position of the double bond of the chalcone.
The best-docked solution of compound 9 (Figure 5A) shows that the compound nicely fits within the upper part of the NES-binding cleft, so that the 2-naphthyl (ring A) has favorable interactions with the hydrophobic residues Ile555, Leu536, Phe583 and Val559, while the pyrimidin-5-yl ring (ring B) is buried in an inner region delimited by Ala552. As for compound 10 (Figure 5B), the best-docked solution indicates that the 3,5-dimethoxyphenyl ring lays in a hydrophobic cavity surrounded by the residues Ile555, Leu536 and Phe583, whereas ring B is directed to the upper part of the cleft. In addition, this binding mode is compatible with a hydrogen bond interaction between the carbonyl group of the ligand and the side chain of Lys579. This stabilizing interaction might help explain the higher inhibitory activity of compound 10 compared to 9 against XPO1. Additionally, this binding mode also suggests that one of the methoxy groups in ring A can be replaced by other longer ethers to gain additional interactions in the lower part of the cleft. Indeed, such ethers (compounds 33 and 34) also showed XPO1 inhibition, but did not improve the inhibitory value of compound 10.

3. Materials and Methods

3.1. Chemistry Procedures

Melting points were measured on a M170 apparatus (Mettler Toledo, Columbus, Ohio, USA) apparatus and are uncorrected. The elemental analysis was performed with a CHN-O-RAPID instrument (Heraus, Hanau, Germany). The elemental compositions of the compounds agreed within ±0.4% of the calculated values.
1H and 13C NMR spectra were recorded on a Varian INNOVA(now Agilent, Santa Clara, CA, USA) 300 operating at 299 MHz (1H) and 75 MHz (13C), respectively, a Varian INNOVA-400 operating at 399 MHZ (1H) and 99 MHz (13C), respectively, and a VARIAN SYSTEM-500 operating at 499 MHz (1H) and 125 MHz (13C), respectively. Monodimensional 1H and 13C spectra were obtained using standard conditions.
Compounds were also analyzed by HPLC/MS with a e2695 LC(Waters, Milford, Massachusetts, USA), coupled to a Waters 2996 photodiode array detector and a Waters Micromass ZQ. The column used is a Waters SunFire C18 2.1 × 50 mm, 3.5 µm, and the mobile phases were A: acetonitrile and B: H2O, together with a constant 5% of C (H2O with 2% formic acid) to assure 0.1% of formic acid along the run.
Analytical TLC was performed on silica gel 60 F254 (Merck, Dramstand, Germany)-precoated plates (0.2 mm). Spots were detected under UV light (254 nm) and/or charring with ninhydrin or phosphomolibdic acid.
Separations on silica gel were performed by preparative centrifugal circular thin-layer chromatography (CCTLC) on a ChromatotronR (Kiesegel 60 PF254 gipshaltig (Merck)), with a layer thickness of 1 and 2 mm and a flow rate of 4 or 8 mL/min, respectively.
General procedure for the reaction of aromatic ethanones with aldehydes under basic conditions (General procedure A) [46].
To a solution of Ba(OH)2·8H2O (1.0–1.2 mmol) in water (0.2 mL), the corresponding aldehyde (1.0–2.0 mmol) in methanol (1 mL) was added. To the resultant mixture, the appropriate aromatic ketone (1.0–1.2 mmol) in methanol (8 mL) was added dropwise over 10 min and the reaction was stirred at room temperature for 2–16 h. The workup and purification procedures are described individually.
General procedure for the reaction of aromatic ketones with pyrimidine-5-carboxaldehyde under acid conditions (General procedure B) [47].
To a mixture containing the corresponding aromatic ketone (1.0 mmol) and pyrimidine-5-carboxaldehyde (1.2–2.8 mmol) in glacial acetic acid (1 mL), piperidine (0.5 mmol) was added dropwise, and then the reaction was stirred at 70–100 °C for 5–48 h. Volatiles were removed, and the residue was purified by CCTLC in the Chromatotron.
General procedure for the alkylation of phenol groups (General procedure C).
To a solution of the corresponding phenol (1.0 mmol) in anhydrous DMF (6 mL), Cs2CO3 (1.2–1.5 mmol) was added. After stirring at rt for 10 min, the appropriate alkyl halide (1.2 mmol) in anhydrous DMF (2 mL) was added dropwise. The resulting mixture was heated at 80 °C for 0.5–5 h and then quenched with water (5 mL). Volatiles were removed and the residue was diluted with ethyl acetate (20 mL) and washed with a saturated solution of NH4Cl (10 mL). The organic layer was dried over Na2SO4, filtered and evaporated to dryness. The residue was purified by CCTLC in the Chromatotron.
(E)-1-(Naphthalen-2-yl)-3-(pyrimidin-5-yl)prop-2-en-1-one (9)
Following the general procedure A, to a solution of Ba(OH)2·8H2O (111 mg, 0.35 mmol) and pyrimidine-5-carboxaldehyde (76 mg, 0.70 mmol) in a mixture of water (70 µL) and methanol (0.4 mL), 1-(naphthalen-2-yl)ethanone (11) (60 mg, 0.35 mmol) in methanol (2.8 mL) was added and the reaction was stirred for 2 h. The reaction was filtered, and the solid obtained was washed with cooled methanol and then purified by CCTLC (petroleum ether/ethyl acetate, 1:1) to yield 50 mg (55%) of 9 as a white solid. Mp: 175–177 °C. MS (ES, positive mode): m/z 261 (M+H)+. 1H NMR (300 MHz, DMSO-d6) δ: 7.61–7.77 (m, 2H, Ar), 7.81 (d, J = 15.8 Hz, 1H, CH=CH-Ar), 7.99–8.13 (m, 2H, Ar), 8.11–8.21 (m, 2H, Ar), 8.40 (d, J = 15.9 Hz, 1H, CH=CH-Ar), 8.99 (s, 1H, Ar), 9.23 (s, 1H, Ar), 9.37 (s, 2H, Ar). 13C NMR (75 MHz, DMSO-d6) δ: 124.4, 125.8, 127.5, 128.1, 129.0, 129.2, 129.3, 130.0, 131.3, 132.6, 134.7, 135.6, 137.3, 157.0, 159.3 (Ar, CH=CH), 188.9 (CO). Anal. calc. for (C17H12N2O): C, 78.44; H, 4.65; N, 10.76. Found: C, 78.19; H, 4.81; N, 10.53.
(E)-2-Methoxycarbonyl-1-(naphthalene-2-yl)-3-(pyrimidin-5-yl)prop-2-en-1-one (13)
Following general procedure B, a solution of methyl 3-(naphthalen-2-yl)-3-oxopropanoate (12) [28] (58 mg, 0.25 mmol), pyrimidine-5-carboxaldehyde (80 mg, 0.70 mmol) and piperidine (13 µL, 0.13 mmol) in glacial acetic acid (1 mL) was stirred at 100 °C overnight and evaporated. The residue was purified by CCTLC in the Chromatotron (DCM/ethyl acetate, 12:1) to yield 32 mg (40%) of 13 as a white solid. Mp: 161–163 °C. MS (ES, positive mode): m/z 319 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 3.76 (s, 3H, OCH3), 7.61 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H, Ar), 7.70 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H, Ar), 7.96–8.04 (m, 2H, Ar), 8.07 (d, J = 8.6 Hz, 1H, Ar), 8.08–8.15 (m, 2H, Ar, C=CH-Ar), 8.58 (d, J = 1.6 Hz, 1H, Ar), 8.77 (s, 2H, Ar), 9.04 (s, 1H, Ar). 13C NMR (101 MHz, DMSO-d6) δ: 53.4 (CH3), 123.7, 127.7, 127.8, 128.3, 129.7, 130.1, 130.4, 132.6, 132.7, 132.8, 134.9, 136.2, 136.6, 157.3, 159.1 (Ar, C=CH), 164.6, 194.5 (CO). Anal. calc. for (C19H14N2O3): C, 71.69; H, 4.43; N, 8.80. Found: C, 71.49; H, 4.53; N, 9.04.
3-(Naphthalen-2-yl)-3-oxopropanamide (14)
The ester 12 (118 mg, 0.52 mmol) was dissolved in NH3/dioxane 0.5 N (2.5 mL) and heated at 110 °C for 7 h. Then, volatiles were removed, and the residue was redissolved in NH3/dioxane 0.5 N (2.5 mL) and heated at 110 °C overnight. Volatiles were removed, and the residue was purified by CCTLC in the Chromatotron (hexane/ethyl acetate, 1:2) to yield 37 mg (34%) of 14 as an amorphous solid containing a tautomeric mixture of the 3-oxopropanamide and 3-hydroxyacrylamide species (ratio 7:3). MS (ES, positive mode): m/z 214 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 4.00 (s, CH2), 5.89 (s, C(OH)=CH), 7.13 (br s, NH2), 7.38 (br s, NH2) 7.55–7.72 (m, Ar), 7.75 (dd, J = 8.7, 1.8 Hz, Ar), 7.94–8.07 (m, Ar), 8.09–8.14 (m, Ar), 8.33 (d, J = 1.9 Hz, Ar), 8.65–8.71 (m, Ar), 15.31 (s, C(OH)=CH).
(E)-2-Carbamoyl-1-(naphthalene-2-yl)-3-(pyrimidin-5-yl)prop-2-en-1-one (15)
Following the general procedure B, a solution of 14 (33 mg, 0.16 mmol), pyrimidine-5-carboxaldehyde (20 mg, 0.19 mmol) and piperidine (10 µL, 0.10 mmol) in glacial acetic acid (1 mL) was stirred at 70 °C for 5 h and evaporated. The residue was purified by CCTLC in the Chromatotron (DCM/methanol, 75:1) to yield 17 mg (36%) of 15 as an amorphous solid. MS (ES, positive mode): m/z 304 (M+H)+. 1H NMR (500 MHz, DMSO-d6) δ: 7.61 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H, Ar), 7.65 (br s, 1H, NH2), 7.69 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H, Ar), 7.74 (s, 1H, C=CH-Ar), 7.93–7.96 (m, 2H, NH2, Ar), 7.99 (d, J = 8.2 Hz, 1H, Ar), 8.03 (d, J = 8.6 Hz, 1H, Ar), 8.08 (d, J = 8.2 Hz, 1H, Ar), 8.49 (s, 1H, Ar), 8.67 (s, 2H, Ar), 8.98 (s, 1H, Ar). 13C NMR (126 MHz, DMSO-d6): 124.0, 127.7, 128.2, 128.6, 129.4, 129.8, 130.2, 130.5, 132.2, 132.5, 133.5, 135.9, 140.0, 156.7, 158.5 (Ar, C=CH), 166.4, 195.8 (CO). Anal. calc. for (C18H13N3O2·0.5H2O): C, 69.22; H, 4.52; N, 13.45. Found: C, 68.95; H, 4.44; N, 13.26.
(E)-2-Methyl-1-(naphthalen-2-yl)-3-(pyrimidin-5-yl)prop-2-en-1-one (18)
Naphthalene was reacted with propionyl chloride as described to provide 1-(naphthalen-2-yl)propan-1-one (17) [30] as the major product, together with a small proportion of its 1-isomer. MS (ES, positive mode): m/z 185 (M+H)+. This mixture (91 mg, 0.49 mmol), pyrimidine-5-carboxaldehyde (144 mg, 1.33 mmol) and piperidine (24 µL, 0.25 mmol) in glacial acetic acid (1 mL) was stirred at 100 °C for 48 h and evaporated, following the general procedure B. The residue was purified by CCTLC in the Chromatotron (DCM/ethyl acetate, 14:1) to yield 42 mg (30%) of 18 as an amorphous solid. MS (ES, positive mode): m/z 275 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 2.26 (d, J = 1.5 Hz, 3H, CH3), 7.17 (s, 1H, C=CH-Ar), 7.63 (ddd, J = 8.1, 6.8, 1.4 Hz, 1H, Ar), 7.68 (ddd, J = 8.2, 6.9, 1.5 Hz, 1H, Ar), 7.87 (dd, J = 8.5, 1.7 Hz, 1H, Ar), 8.03 (d, J = 8.0 Hz, 1H, Ar), 8.07 (d, J = 8.6 Hz, 1H, Ar), 8.13 (d, J = 8.1 Hz, 1H, Ar), 8.44 (s, 1H, Ar), 8.99 (s, 2H, Ar), 9.17 (s, 1H, Ar). 13C NMR (126 MHz, DMSO-d6) δ: 15.2 (CH3), 125.8, 127.4, 128.1, 128.8, 128.9, 129.9, 130.2, 131.5, 132.4, 133.7, 134.7, 135.1, 140.3, 157.5, 157.8 (Ar, C=CH), 198.2 (CO). Anal. calc. for (C18H14N2O): C, 78.81; H, 5.14; N, 10.21. Found: C, 78.39; H, 5.12; N, 9.89.
3-(Naphthalen-2-yl)-3-oxopropanenitrile (20) [32]
An Ace pressure tube was charged with a solution of methyl 2-naphthoate (19) (250 mg, 1.34 mmol) and acetonitrile (210 μL, 4.03 mmol) in anhydrous toluene (2.7 mL). Then, NaH (60% dispersion in mineral oil, 162 mg, 4.03 mmol) was added, and the resulting mixture was heated to 110 °C overnight. The reaction was allowed to warm to rt and quenched with water (5 mL). Then, it was diluted with DCM (15 mL) and washed with HCl 1N (10 mL) and brine. The organic layer was dried over Na2SO4, filtered and evaporated to dryness. The residue was purified by flash chromatography (DCM/methanol, 100:1) to yield 125 mg (48%) of 20 as an amorphous solid. MS (ES, positive mode): m/z 196 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 4.89 (s, 2H, CH2), 7.66 (ddd, J = 8.1, 6.8, 1.4 Hz, 1H, Ar), 7.72 (ddd, J = 8.2, 6.8, 1.4 Hz, 1H, Ar), 7.96 (dd, J = 8.6, 1.8 Hz, 1H, Ar), 8.03 (d, J = 8.0 Hz, 1H, Ar), 8.06 (d, J = 8.7 Hz, 1H, Ar), 8.12 (d, J = 7.9 Hz, 1H, Ar), 8.65 (m, 1H, Ar). 1H NMR data are similar to those previously described [32].
(E)-2-Cyano-1-(naphthalene-2-yl)-3-(pyrimidin-5-yl)prop-2-en-1-one (21)
Following the general procedure B, a solution of 20 (30 mg, 0.15 mmol), pyrimidine-5-carbaldehyde (23 mg, 0.21 mmol) and piperidine (8 µL, 0.08 mmol) in glacial acetic acid (1 mL) was heated to 70 °C for 2 h and evaporated. After cooling down with an ice bath and adding cold ethanol (3 mL), a solid precipitated, which was filtered under vacuum and washed with cold ethanol to yield 16 mg (36%) of 21 as an amorphous yellow solid. MS (ES, positive mode): m/z 286 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 7.65–7.77 (m, 2H, Ar), 7.94 (dd, J = 8.5, 1.8 Hz, 1H, Ar), 8.07 (d, J = 8.1 Hz, 1H, Ar), 8.11–8.18 (m, 2H, Ar), 8.34 (s, 1H, C=CH-Ar), 8.66 (d, J = 1.8 Hz, 1H, Ar), 9.36 (s, 1H, Ar), 9.38 (s, 2H, Ar).
(E)-1-(Naphthalen-2-yl)-3-(pyridin-3-yl)prop-2-en-1-one (24)
Following the general procedure A, to a solution of Ba(OH)2·8H2O (111 mg, 0.35 mmol) and 3-pyridinecarboxaldehyde (21) (66 μL, 0.70 mmol) in water (70 µL) and methanol (0.4 mL), 1-(naphthalen-2-yl)ethanone (11) (60 mg, 0.35 mmol) in methanol (2.8 mL) was added, and the reaction was stirred for 3 h. Volatiles were removed, and the residue was purified by CCTLC (hexane/ethyl acetate, 1:1) to yield 67 mg (73%) of 24 as a pale yellow solid. Mp: 123–125 °C. MS (ES, positive mode): m/z 260 (M+H)+. 1H NMR (300 MHz, DMSO-d6) δ: 7.53 (dd, J = 8.0, 4.8 Hz, 1H, Ar), 7.60–7.77 (m, 2H, Ar), 7.85 (d, J = 15.7 Hz, 1H, CH=CH-Ar), 7.97–8.13 (m, 2H, Ar), 8.10–8.22 (m, 2H, Ar), 8.28 (d, J = 15.7 Hz, 1H, CH=CH-Ar), 8.41 (dt, J = 8.1, 1.9 Hz, 1H, Ar), 8.64 (dd, J = 4.8, 1.6 Hz, 1H, Ar), 8.98 (s, 1H, Ar), 9.09 (d, J = 2.2 Hz, 1H, Ar). 13C NMR (75 MHz, DMSO-d6) δ: 124.3, 124.4, 127.4, 128.1, 128.9, 129.2, 130.0, 131.0, 131.1, 132.7, 135.0, 135.5, 135.6, 140.8, 150.7, 151.4 (Ar, CH=CH), 189.0 (C=O). Anal. calc. for (C18H13NO): C, 83.37; H, 5.05; N, 5.40. Found: C, 83.36; H, 5.23; N, 5.46. This compound has been recently described using slightly different reaction conditions [48].
(E)-1-(Naphthalen-2-yl)-3-(pyridin-2-yl)prop-2-en-1-one (25)
Following the general procedure A, to a solution of Ba(OH)2·8H2O (111 mg, 0.35 mmol) and 2-pyridinecarboxaldehyde (22) (67 μL, 0.70 mmol) in water (70 µL) and methanol (0.4 mL), 1-(naphthalen-2-yl)ethanone (11) (60 mg, 0.35 mmol) in methanol (2.8 mL) was added, and the reaction was stirred for 7 h. Volatiles were removed, and the residue was purified by CCTLC (hexane/ethyl acetate, 6:1) to yield 37 mg (40%) of 25 as a pale yellow solid. Mp: 89–90 °C. MS (ES, positive mode): m/z 260 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 7.47 (ddd, J = 6.9, 4.7, 2.4 Hz, 1H, Ar), 7.62–7.73 (m, 2H, Ar), 7.80 (d, J = 15.4 Hz, 1H, CH=CH-Ar), 7.90–7.97 (m, 2H, Ar), 8.03 (d, J = 8.0 Hz, 1H, Ar), 8.04–8.15 (m, 2H, Ar), 8.23 (d, J = 7.9 Hz, 1H, Ar), 8.34 (d, J = 15.4 Hz, 1H, CH=CH-Ar), 8.72 (d, J = 4.5 Hz, 1H, Ar), 8.88 (d, J = 1.8 Hz, 1H, Ar). 13C NMR (101 MHz, DMSO-d6) δ: 124.4, 125.3, 125.6, 127.5, 128.2, 129.1, 129.3, 130.3, 131.0, 132.8, 135.1, 135.6, 137.7, 143.5, 150.5, 153.3 (Ar, CH=CH), 189.7 (CO). Anal. calc. for (C18H13NO): C, 83.37; H, 5.05; N, 5.40. Found: C, 83.22; H, 5.08; N, 5.26. This compound has been recently described using slightly different reaction conditions [48].
(E)-1-(Naphthalen-2-yl)-3-(pyridin-4-yl)prop-2-en-1-one (26)
Following the general procedure A, to a solution of Ba(OH)2·8H2O (111 mg, 0.35 mmol) and 4-pyridinecarboxaldehyde (23) (52 μL, 0.53 mmol) in water (70 µL) and methanol (0.5 mL), 1-(naphthalen-2-yl)ethanone (11) (60 mg, 0.35 mmol) in methanol (2.8 mL) was added and the reaction was stirred for 2 h. Water was added, and the resulting solid was isolated and then purified by CCTLC (hexane/ethyl acetate/triethylamine, 3:1:0.04) to yield 30 mg (32%) of 26 as a pale yellow solid. Mp: 135–137 °C. MS (ES, positive mode): m/z 260 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 7.64–7.73 (m, 2H, Ar), 7.76 (d, J = 15.7 Hz, 1H, CH=CH-Ar), 7.87–7.92 (m, 2H, Ar), 8.01–8.10 (m, 2H, Ar), 8.12–8.20 (m, 2H, Ar), 8.35 (d, J = 15.7 Hz, 1H, CH=CH-Ar), 8.68–8.73 (m, 2H, Ar), 8.98 (s, 1H, Ar). 13C NMR (126 MHz, DMSO-d6) δ: 123.0, 124.5, 126.8, 127.5, 128.2, 129.1, 129.4, 130.1, 131.4, 132.7, 134.8, 135.7, 141.4, 142.3, 150.8 (Ar, CH=CH), 189.3 (CO). Anal. calc. for (C18H13NO): C, 83.37; H, 5.05; N, 5.40. Found: C, 83.30; H, 5.00; N, 5.18. This compound has been recently described using slightly different reaction conditions [48].
(E)-1-(3′,5′-Dimethoxyphenyl)-3-(pyrimidin-5′’-yl)prop-2-en-1-one (10)
Following the general procedure A, to a solution of Ba(OH)2·8H2O (132 mg, 0.42 mmol) and pyrimidine-5-carbaldehyde (91 mg, 0.84 mmol) in water (84 µL) and methanol (0.5 mL), 1-(3,5-dimethoxyphenyl)ethan-1-one (28) [33] (76 mg, 0.42 mmol) in methanol (3.4 mL) was added, and the reaction was stirred overnight. The reaction was filtered and the solid obtained was washed with cooled methanol and then purified by CCTLC in the Chromatotron (hexane/ethyl acetate, 1:3) to yield 72 mg (64%) of 10 as a white solid. Mp: 184–185 °C. MS (ES, positive mode): m/z 271 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 3.85 (s, 6H, OCH3), 6.83 (t, J = 2.3 Hz, 1H, Ar), 7.31 (d, J = 2.3 Hz, 2H, Ar), 7.74 (d, J = 15.8 Hz, 1H, CH=CH-Ar), 8.17 (d, J = 15.8 Hz, 1H, CH=CH-Ar), 9.21 (s, 1H, Ar), 9.34 (s, 2H, Ar). 13C NMR (101 MHz, DMSO-d6) δ: 56.1 (OCH3), 105.9, 106.9, 125.8, 129.2, 137.8, 139.5, 157.2, 159.4, 161.2 (Ar, CH=CH), 188.7 (CO). Anal. calc. for (C15H14N2O3): C, 66.66; H, 5.22; N, 10.36. Found: C, 66.79; H, 5,24; N, 10,33.
(E)-2-Methoxycarbonyl-1-(3′,5′-dimethoxybenzoyl)-3-(pyrimidin-5′-yl)prop-2-en-1-one (30)
Following the general procedure B, a solution of methyl 3-(3′,5′-dimethoxyphenyl)-3-oxopropanoate (29) [34] (50 mg, 0.21 mmol), pyrimidine-5-carbaldehyde (31 mg, 0.29 mmol) and piperidine (10 µL, 0.10 mmol) in acetic acid (1 mL) was stirred at 70 °C overnight and evaporated. The residue was purified by CCTLC in the Chromatotron (hexane/ethyl acetate, 1:1) to yield 27 mg (39%) of 30 as a pale yellow solid. Mp: 81–82 °C. MS (ES, positive mode): m/z 329 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 3.76 (s, 3H, COOCH3), 3.77 (s, 6H, OCH3), 6.83 (t, J = 2.3 Hz, 1H, Ar), 7.00 (d, J = 2.3 Hz, 2H, Ar), 8.00 (s, 1H, C=CH-Ar), 8.73 (s, 2H, Ar), 9.10 (s, 1H, Ar). 13C NMR (75 MHz, DMSO-d6) δ: 53.1 (COOCH3), 55.9 (OCH3), 106.9, 127.6, 134.4, 136.4, 137.1, 157.2, 159.1, 161.3 (Ar, CH=CH), 164.4 (COOCH3), 193.83 (CO). Anal. calc. for (C17H16N2O5): C, 62.19; H, 4.91; N, 8.53. Found: C, 62.56; H, 4.99; N, 8.20.
1-(3-Methoxy-5-(2-methoxyethoxy)phenyl)ethan-1-one (31)
3,5-Dihydroxyacetophenone (27) was reacted with methyl iodide as described [49] to provide 1-(3-hydroxy-5-methoxyphenyl)ethan-1-one (MS (ES, positive mode): m/z 167 (M+H)+) together with 1-(3,5-dimethoxyphenyl)ethan-1-one (28). The 3-hydroxy derivative (52 mg, 0.31 mmol) was reacted with Cs2CO3 (151 mg, 0.46 mmol) and 2-bromoehtyl methyl ether (34 µL, 0.37 mmol) in anhydrous DMF (0.9 mL) at 80 °C for 5 h, following the general procedure C. After workup, the residue was purified by CCTLC in the Chromatotron (DCM/ethyl acetate, 40:1) to yield 54 mg (77%) of 31 as a colourless oil. MS (ES, positive mode): m/z 225 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 2.55 (s, 3H, COCH3), 3.31 (s, 3H, OCH3), 3.63–3.68 (m, 2H, OCH2), 3.80 (s, 3H, OCH3), 4.11–4.17 (m, 2H, OCH2), 6.78 (t, J = 2.3 Hz, 1H, Ar), 7.06 (m, 1H, Ar), 7.08 (m, 1H, Ar).
1-(3-Methoxy-5-((3-methylbut-2-en-1-yl)oxy)phenyl)ethan-1-one (32)
As described for the synthesis of 31, 1-(3-hydroxy-5-methoxyphenyl)ethan-1-one (67 mg, 0.40 mmol) was reacted with Cs2CO3 (196 mg, 0.60 mmol) and 3,3-dimethylallylbromide (58 µL, 0.48 mmol) in anhydrous DMF (1.2 mL) at 80 °C for 1 h, following the general procedure C. After workup, the residue was purified by CCTLC in the Chromatotron (DCM/ethyl acetate, 80:1) to yield 71 mg (75%) of 32 as a colourless oil. MS (ES, positive mode): m/z 235 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 1.72 (s, 3H, CH3), 1.74 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 4.58 (d, J = 6.8 Hz, 2H, OCH2CH), 5.42 (m, 1H, OCH2CH), 6.76 (t, J = 2.3 Hz, 1H, Ar), 7.04 (dd, J = 2.3, 1.4 Hz, 1H, Ar), 7.07 (dd, J = 2.3, 1.3 Hz, 1H, Ar).
(E)-1-(3′-Methoxy-5′-(2-methoxyethoxy)phenyl)-3-(pyrimidin-5′’-yl)prop-2-en-1-one (33)
Following the general procedure A, to a solution of Ba(OH)2·8H2O (94 mg, 0.30 mmol) and pyrimidine-5-carbaldehyde (40 mg, 0.37 mmol) in water (60 µL) and methanol (0.3 mL), the ketone 31 (69 mg, 0.30 mmol) in methanol (2.4 mL) was added, and the reaction was stirred for 1.5 h. Volatiles were removed, and the residue was purified by CCTLC in the Chromatotron (DCM/MeOH, 80:1) to yield 29 mg (32%) of 33 as an amorphous white solid. MS (ES, positive mode): m/z 325 (M+H)+. 1H NMR (400 MHz, DMSO-d6) δ: 3.32 (s, 3H, OCH3), 3.67–3.71 (m, 2H, OCH2), 3.84 (s, 3H, OCH3), 4.17–4.22 (m, 2H, OCH2), 6.84 (d, J = 2.3 Hz, 1H, Ar), 7.29 (dd, J = 2.3, 1.3 Hz, 1H, Ar), 7.34 (dd, J = 2.3, 1.4 Hz, 1H, Ar), 7.74 (d, J = 15.8 Hz, 1H, CH=CH-Ar), 8.17 (d, J = 15.8 Hz, 1H, CH=CH-Ar), 9.20 (s, 1H, Ar), 9.34 (s, 2H, Ar). 13C NMR (101 MHz, DMSO-d6) δ: 56.1, 58.6, 67.8, 70.8 (CH2, CH3), 106.3, 106.8, 107.7, 125.8, 129.2, 137.8, 139.5, 157.2, 159.4, 160.5, 161.2 (Ar, CH=CH), 188.7 (CO). Anal. calc. for (C17H18N2O4): C, 64.96; H, 5.77; N, 8.91. Found: C, 64.59; H, 5.68; N, 8.78.
(E)-1-(3′-Methoxy-5′-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(pyrimidin-5′’-yl)prop-2-en-1-one (34)
Following the general procedure A, to a solution of Ba(OH)2·8H2O (82 mg, 0.26 mmol) and pyrimidine-5-carbaldehyde (34 mg, 0.31 mmol) in water (52 µL) and methanol (0.26 mL), the ketone 32 (61 mg, 0.26 mmol) in methanol (2.1 mL) was added and the reaction was stirred for 2 h. Water was added, and the resulting solid was isolated and then purified by CCTLC in the Chromatotron (hexane/ethyl acetate, 1:1) to yield 39 mg (41%) of 34 as an amorphous white solid. MS (ES, positive mode): m/z 325 (M+H)+. 1H NMR (300 MHz, DMSO-d6) δ: 1.74 (s, 3H, CH3), 1.75 (s, 3H, CH3), 3.84 (s, 3H, OCH3), 4.62 (d, J = 6.8 Hz, 2H, OCH2CH), 5.42 (m, 1H, OCH2CH), 6.82 (t, J = 2.2 Hz, 1H, Ar), 7.28 (t, J =2.2 Hz, 1H, Ar), 7.32 (t, J = 2.3 Hz, 1H, Ar) 7.73 (d, J = 15.8 Hz, 1H, CH=CH-Ar), 8.16 (d, J = 15.8 Hz, 1H, CH=CH-Ar), 9.20 (s, 1H, Ar), 9.34 (s, 2H, Ar). 13C NMR (101 MHz, DMSO-d6) δ: 18.5, 25.9, 56.1, 65.2 (CH2, CH3), 106.5, 106.6, 107.9, 120.0, 125.80, 129.2, 137.7, 138.1, 139.4, 157.2, 159.3, 160.4, 161.2 (Ar, CH=CH, C(CH3)2=CH), 188.7 (CO). Anal. calc. for (C19H20N2O3): C, 70.35; H, 6.21; N, 8.64. Found: C, 70.21; H, 6.29; N, 8.35.

3.2. GSH Reactivity Assay

A 500 µM sample of the tested compound was incubated with 5 mM reduced L-glutathione for 24 h at 37 °C with a final volume of 200 μL. As a solvent system, 20 mM PBS buffer pH 7.4 with 2 mM EDTA:DMSO (1:1) was used [50]. To perform the assay, stock solutions of 20 mM of the chalcones (9, 10, 13 and 18) and 15 mM of reduced L-glutathione were freshly prepared for every experiment and then diluted properly to give the final electrophile:nucleophile ratio (1:10). A 5 mM solution of 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) was prepared in the same solvent system to quench the reaction. After different time points (10 min, 1 h, 4 h and 24 h), an aliquot of 20 μL of the incubation mixture was quenched by adding 20 μL of the DTNB stock solution, mixed thoroughly, and then analyzed by HPLC. HPLC analysis was performed in Agilent 1120 compact LC, column ACE 5 C18-300 (15 cm × 4.6 mm); UV detection was performed at λ = 254 nm. Solvents used were acetonitrile for bottle A and H2O (containing 0.05% TFA) for bottle B, and the flow rate was 1mL/min. The gradients used were: (A) incubations with chalcone 9: from 10% to 80% of solvent A in 10 min; (B) incubations with chalcones 10 and 18: from 10% to 100% of solvent A in 10 min. The new peaks were analysed by LC-MS. As controls, a 500 μM solution of the α,β-unsaturated compound was also analysed, and a 5 mM reduced L-glutathione solution was quenched by adding DNTB at the same time points. In general, after 6 h of incubation, no GSH was detected.

3.3. Biological Assays

3.3.1. Cell Culture and Reference Compounds

Cancer cell lines HCT-116, NCI-H460, HL-60, K-562 and Z-138 were acquired from the American Type Culture Collection (ATCC, Manassas, VA, USA). The DND-41 cell line was purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ Leibniz-Institut, Brunswick, Germany), and the HAP-1 cell line was ordered from Horizon Discovery (Horizon Discovery Group, Water Beach, UK). All cell lines were cultured as recommended by the suppliers. Culture media were purchased from Gibco Life Technologies and supplemented with 10% fetal bovine serum (HyClone, GE Healthcare Life Sciences, Chicago, Illinois, USA).
Stably transfected HeLa NLSSV40-AcGFP-NESPKI were cultured as described in Vercruysse et al. [19] CRISPR/Cas9 genome editing of the Jurkat cell line was performed as in Neggers et al. [43] to generate a XPO1C528S mutant cell line.
Reference inhibitor KPT-330 was purchased from Selleckchem, and stock solutions were prepared in DMSO.

3.3.2. Cell Proliferation Assays

Adherent cell lines HCT-116, NCI-H460 and Hap-1 cells were seeded at a density between 500 and 1500 cells per well in 384-well tissue culture plates (Greiner). After overnight incubation, cells were treated with different concentrations of the test compounds. Suspension cell lines HL-60, K-562, Z-138 and DND-41 were seeded at densities ranging from 2500 to 5500 cells per well in 384-well culture plates containing the test compounds at the same concentration points. The plates were incubated and monitored at 37 °C for 72 h in an IncuCyte (Essen BioScience Inc., Sartorius; Göttingen, Germany for real-time imaging of cell proliferation. Brightfield images were taken every 3 h, with one field imaged per well under 10× magnification. Cell growth was then quantified based on the percent cellular confluence, as analysed by the IncuCyte image analysis software, and used to calculate IC50 values by logarithmic interpolation. Compounds were tested in two independent experiments and represented as mean ± SEM.

3.3.3. XPO1 Phenotypic Reporter Assay

To study the XPO1-mediated nuclear export, stably transfected HeLa NLSSV40-AcGFP-NESPKI reporter cells were seeded at 8000 cells per well in 96-well all clear tissue culture plates (TPP). After overnight incubation, cells were treated with different doses of compound or solvent (DMSO) for 2 h and then fixed and counterstained with DAPI. Fluorescence was read on an ArrayScan XTI High Content Reader (Thermo Fisher Scientific, Waltham, MA, USA). Nuclear and cytoplasmic compartments were segmented and their average pixel intensities in the green channel were quantitated employing the HCS Studio software. Genedata Screener software was used for dose-response curve fitting, and calculation of EC50 values was based on the percentage of cells having a predominant nuclear localisation (ratio of nuclear to cytoplasmic signal equal or above 1.4) of the reporter construct. Compounds were tested in two independent experiments and represented as mean ± SEM.

3.3.4. Immunofluorescence Staining of RanBP1

RanBP1 immunofluorescence staining was performed on both wild type and mutant XPO1C528S Jurkat cells treated with compound or solvent (DMSO) for 3 h. Cells were harvested at 400× g, washed in PBS and then transferred into an 8-well µ-Slide (Ibidi) pretreated with 0.1% (w/v) poly-L-lysine (Sigma). Cells were allowed to adhere to the slides and then subsequently fixed (4% PFA in PBS), washed and permeabilized (0.2% Triton X-100 in PBS). Further immunofluorescence staining was then performed according to standard procedures. Employed antibodies were rabbit anti-RanBP1 (ab97659, Abcam, Cambridge, UK) at a 1:500 dilution and secondary Alexa Fluor 488 goat anti-rabbit antibody (A11008, Invitrogen, ThermoFisher Scientific). Cell nuclei were counterstained with DAPI, and the samples were imaged by confocal microscopy on a Leica TCS SP5 confocal microscope (Leica Microsystems, Weitzlar, Germany), employing a HCX PL APO 63× (NA 1.2) water immersion objective. Subsequently, fluorescence was read on an ArrayScan XTI High Content Reader (Thermo Fisher Scientific, Waltham, MA, USA). Nuclear and cytoplasmic compartments were segmented, and their average pixel intensities in the green channel were quantitated similarly as for the XPO1 phenotypic reporter assay.

3.4. Computational Methods

The crystal structure of XPO1 complex with KPT-8602 was retrieved from the Protein Data Bank [51] (pdb id: 5JLJ [20]).
The Schrödinger Suite v2018-3 has been used for all the computational studies [52]. The 3D structure of all compounds used in the modelling studies were generated using the graphical interface Maestro, and these were then optimized using the tool Macromodel. For the docking studies, all ligands were prepared with LigPrep in Maestro, and the receptor protein was prepared with the Protein Preparation Wizard.
Covalent docking was performed with CovDock [44]. The KPT-8602-XPO1 X-Ray structure was used for all covalent docking studies. Cys539 was selected as the reactive residue and Michael addition was selected as the reaction type. A grid box of 10 Å was defined. CovDock was used with the default parameters published in reference [44], except for the number of final poses per ligand, which was set up to 10. MMGBSA analysis was also chosen. Results were visually inspected and analysed using the computer graphics program PyMOL [53].

4. Conclusions

Most of the described XPO1 inhibitors are α,β-unsaturated carbonyl compounds able to react with Cys528 at the NES-binding cleft of XPO1. Based on these examples, we synthesized two series of chalcones with a six-membered N-heterocycle as ring B and tested their XPO1 inhibitory activity. Most of the synthesized compounds inhibited XPO1 function in a reporter cell line, and this inhibition nicely correlated with their antiproliferative activity in cell culture assays, with compounds 9, 10, 24 and 34 as the most potent. Moreover, in a mutant Jurkat cell line where the Cys528 of XPO1 had been mutated to a Ser (Jurkat XPO1C528S), the capacity of the prototype compounds 9 and 10 to inhibit XPO1 mediated nuclear export of the cargo protein was abolished, indicating the importance of Cys at position 528 for the inhibitory activity of our compounds, as also demonstrated for KPT-330 [43]. Finally, the interaction of the chalcones 9 and 10 with the NES-binding cleft has been analyzed through covalent docking with CovDock. Thus, these chalcones may represent an alternative scaffold in the search for XPO1 inhibitors.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ph14111131/s1, Figures S1–S4: Chromatograms of the incubations of chalcones 9, 10, 13 and 18 with GSH. 1H and 13C NMR spectra of the tested compounds.

Author Contributions

Conceptualization, M.-J.C., D.D., E.-M.P. and M.-J.P.-P.; formal analysis, E.-M.P.; investigation, M.G., J.L.-F. and L.P.; project administration, M.-J.P.-P.; supervision, D.D. and M.-J.P.-P.; validation, M.G. and L.P.; visualization, E.-M.P.; writing—original draft, M.G., D.D., E.-M.P. and M.-J.P.-P.; writing—review & editing, M.-J.C. and M.-J.P.-P. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by AECSIC, grant number PIE-201980E100 and by Agencia Estatal de Investigación (PID2019-105117RR-C22/ AEI / 10.13039/501100011033 and PID2019-104070RB-C21).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article or supplementary material.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kim, Y.H.; Han, M.-E.; Oh, S.-O. The molecular mechanism for nuclear transport and its application. Anat. Cell Biol. 2017, 50, 77–85. [Google Scholar] [CrossRef] [PubMed]
  2. Kosyna, F.K.; Depping, R. Controlling the Gatekeeper: Therapeutic Targeting of Nuclear Transport. Cells 2018, 7, 221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Pickens, J.A.; Tripp, R.A. Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses. Viruses 2018, 10, 48. [Google Scholar] [CrossRef] [Green Version]
  4. Çağatay, T.; Chook, Y.M. Karyopherins in cancer. Curr. Opin. Cell Biol. 2018, 52, 30–42. [Google Scholar] [CrossRef]
  5. Mathew, C.; Ghildyal, R. CRM1 Inhibitors for Antiviral Therapy. Front. Microbiol. 2017, 8, 1171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Camus, V.; Miloudi, H.; Taly, A.; Sola, B.; Jardin, F. XPO1 in B cell hematological malignancies: From recurrent somatic mutations to targeted therapy. J. Hematol. Oncol. 2017, 10, 1–13. [Google Scholar] [CrossRef] [Green Version]
  7. Sun, Q.; Chen, X.; Zhou, Q.; Burstein, E.; Yang, S.; Jia, D. Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal Transduct. Target. Ther. 2016, 1, 1–10. [Google Scholar] [CrossRef] [Green Version]
  8. Dickmanns, A.; Monecke, T.; Ficner, R. Structural Basis of Targeting the Exportin CRM1 in Cancer. Cells 2015, 4, 538–568. [Google Scholar] [CrossRef] [Green Version]
  9. Muqbil, I.; Azmi, A.S.; Mohammad, R.M. Nuclear Export Inhibition for Pancreatic Cancer Therapy. Cancers 2018, 10, 138. [Google Scholar] [CrossRef] [Green Version]
  10. A Jans, D.; Martin, A.J.; Wagstaff, K.M. Inhibitors of nuclear transport. Curr. Opin. Cell Biol. 2019, 58, 50–60. [Google Scholar] [CrossRef] [PubMed]
  11. Yoshimura, M.; Ishizawa, J.; Ruvolo, V.; Dilip, A.; Quintás-Cardama, A.; McDonnell, T.J.; Neelapu, S.S.; Kwak, L.; Shacham, S.; Kauffman, M.; et al. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO 1) inhibition in mantle cell lymphoma. Cancer Sci. 2014, 105, 795–801. [Google Scholar] [CrossRef] [PubMed]
  12. Daelemans, D.; Afonina, E.; Nilsson, J.; Werner, G.; Kjems, J.; De Clercq, E.; Pavlakis, G.N.; Vandamme, A.-M. A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc. Natl. Acad. Sci. USA 2002, 99, 14440–14445. [Google Scholar] [CrossRef] [Green Version]
  13. Van Neck, T.; Pannecouque, C.; Vanstreels, E.; Stevens, M.; Dehaen, W.; Daelemans, D. Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: Structure–activity relationship and mechanism of action. Bioorg. Med. Chem. 2008, 16, 9487–9497. [Google Scholar] [CrossRef]
  14. Lapalombella, R.; Sun, Q.; Williams, K.; Tangeman, L.; Jha, S.; Zhong, Y.; Goettl, V.; Mahoney, E.; Berglund, C.; Gupta, S.; et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood 2012, 120, 4621–4634. [Google Scholar] [CrossRef] [Green Version]
  15. Lei, Y.; An, Q.; Shen, X.-F.; Sui, M.; Li, C.; Jia, D.; Luo, Y.; Sun, Q. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1. J. Med. Chem. 2021, 64, 6596–6607. [Google Scholar] [CrossRef] [PubMed]
  16. Shaikhqasem, A.; Dickmanns, A.; Neumann, P.; Ficner, R. Characterization of Inhibition Reveals Distinctive Properties for Human and Saccharomyces cerevisiae CRM1. J. Med. Chem. 2020, 63, 7545–7558. [Google Scholar] [CrossRef]
  17. Sun, Q.; Carrasco, Y.P.; Hu, Y.; Guo, X.; Mirzaei, H.; MacMillan, J.; Chook, Y.M. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1. Proc. Natl. Acad. Sci. USA 2013, 110, 1303–1308. [Google Scholar] [CrossRef] [Green Version]
  18. Van Der Watt, P.J.; Chi, R.-P.A.; Stelma, T.; Stowell, C.; Strydom, E.; Carden, S.; Angus, L.; Hadley, K.; Lang, D.; Wei, W.; et al. Targeting the Nuclear Import Receptor Kpnβ1 as an Anticancer Therapeutic. Mol. Cancer Ther. 2016, 15, 560–573. [Google Scholar] [CrossRef] [Green Version]
  19. Vercruysse, T.; De Bie, J.; Neggers, J.; Jacquemyn, M.; Vanstreels, E.; Schmid-Burgk, J.; Hornung, V.; Baloglu, E.; Landesman, Y.; Senapedis, W.; et al. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia. Clin. Cancer Res. 2017, 23, 2528–2541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Hing, Z.A.; Fung, H.Y.J.; Ranganathan, P.; Mitchell, S.; El-Gamal, D.; Woyach, J.A.; Williams, K.; Goettl, V.M.; Smith, J.; Yu, X.; et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia 2016, 30, 2364–2372. [Google Scholar] [CrossRef] [Green Version]
  21. FDA Grants Accelerated Approval to Selinexor for Multiple Myeloma|FDA. Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-selinexor-multiple-myeloma (accessed on 24 September 2021).
  22. Sakakibara, K.; Saito, N.; Sato, T.; Suzuki, A.; Hasegawa, Y.; Friedman, J.; Kufe, D.W.; Vonhoff, D.D.; Iwami, T.; Kawabe, T. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011, 118, 3922–3931. [Google Scholar] [CrossRef] [PubMed]
  23. Liu, X.; Chong, Y.; Liu, H.; Han, Y.; Niu, M. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer. J. Ovarian Res. 2015, 8, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors. Available online: https://clinicaltrials.gov/ct2/show/NCT02667873 (accessed on 4 October 2021).
  25. Etchin, J.; Sun, Q.; Kentsis, A.; Farmer, A.; Zhang, Z.C.; Sanda, T.; Mansour, M.; Barceló, C.; McCauley, D.; Kauffman, M.; et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2012, 27, 66–74. [Google Scholar] [CrossRef]
  26. Bradshaw, J.M.; McFarland, J.M.; Paavilainen, V.O.; Bisconte, A.; Tam, D.; Phan, V.T.; Romanov, S.; Finkle, D.; Shu, J.; Patel, V.; et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat. Chem. Biol. 2015, 11, 525–531. [Google Scholar] [CrossRef] [Green Version]
  27. Al-Rifai, N.; Rücker, H.; Amslinger, S. Opening or Closing the Lock? When Reactivity Is the Key to Biological Activity. Chem. A Eur. J. 2013, 19, 15384–15395. [Google Scholar] [CrossRef] [PubMed]
  28. Murphy, G.K.; Tao, J.; Tuck, T.N. Geminal Dichlorination of Phenyliodonium Ylides of β-Dicarbonyl Compounds through Double Ligand Transfer from (Dichloroiodo)benzene. Synthesis 2016, 48, 772–782. [Google Scholar] [CrossRef]
  29. Zheng, X.; Kerr, M.A. Synthesis and Cross-Coupling Reactions of 7-Azaindoles via a New Donor−Acceptor Cyclopropane. Org. Lett. 2006, 8, 3777–3779. [Google Scholar] [CrossRef]
  30. Ghosh, A.K.; Takayama, J.; Aubin, Y.; Ratia, K.; Chaudhuri, R.; Baez, Y.; Sleeman, K.; Coughlin, M.; Nichols, D.B.; Mulhearn, D.C.; et al. Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome−Coronavirus Papain-Like Protease. J. Med. Chem. 2009, 52, 5228–5240. [Google Scholar] [CrossRef] [Green Version]
  31. Malmedy, F.; Wirth, T. Stereoselective Ketone Rearrangements with Hypervalent Iodine Reagents. Chem. A Eur. J. 2016, 22, 16072–16077. [Google Scholar] [CrossRef] [Green Version]
  32. Romagnoli, R.; Baraldi, P.G.; Carrion, M.D.; Cara, C.L.; Salvador, M.K.; Preti, D.; Tabrizi, M.A.; Moorman, A.R.; Vincenzi, F.; Borea, P.A.; et al. Synthesis and biological effects of novel 2-amino-3-(4-chlorobenzoyl)-4-substituted thiophenes as allosteric enhancers of the A1 adenosine receptor. Eur. J. Med. Chem. 2013, 67, 409–427. [Google Scholar] [CrossRef] [PubMed]
  33. Jimenez, L.R.; Tolentino, D.R.; Gallon, B.J.; Schrodi, Y. Development of a Method for the Preparation of Ruthenium Indenylidene-Ether Olefin Metathesis Catalysts. Molecules 2012, 17, 5675–5689. [Google Scholar] [CrossRef] [Green Version]
  34. Parsons, D.E.; Frontier, A.J. Noncanonical Cation−π Cyclizations of Alkylidene β-Ketoesters: Synthesis of Spiro-fused and Bridged Bicyclic Ring Systems. Org. Lett. 2019, 21, 2008–2012. [Google Scholar] [CrossRef] [PubMed]
  35. Heinelt, U.; Wehner, V.; Herrmann, M.; Schoenafinger, K.; Steinhagen, H. Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments. PCT Int. Appl. WO200909 7971A1, 2009.
  36. Ducki, S.; Forrest, R.; Hadfield, J.A.; Kendall, A.; Lawrence, N.J.; McGown, A.T.; Rennison, D. Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. 1998, 8, 1051–1056. [Google Scholar] [CrossRef]
  37. Lawrence, N.J.; Patterson, R.P.; Ooi, L.-L.; Cook, D.; Ducki, S. Effects of α-substitutions on structure and biological activity of anticancer chalcones. Bioorg. Med. Chem. Lett. 2006, 16, 5844–5848. [Google Scholar] [CrossRef] [PubMed]
  38. Biddle, M.M.; Lin, M.; Scheidt, K.A. Catalytic Enantioselective Synthesis of Flavanones and Chromanones. J. Am. Chem. Soc. 2007, 129, 3830–3831. [Google Scholar] [CrossRef] [PubMed]
  39. Böhme, A.; Thaens, D.; Paschke, A.; Schüürmann, G. Kinetic Glutathione Chemoassay To Quantify Thiol Reactivity of Organic Electrophiles—Application to α,β-Unsaturated Ketones, Acrylates, and Propiolates. Chem. Res. Toxicol. 2009, 22, 742–750. [Google Scholar] [CrossRef]
  40. Chan, K.; Poon, R.; O’Brien, P.J. Application of structure–activity relationships to investigate the molecular mechanisms of hepatocyte toxicity and electrophilic reactivity ofα,β-unsaturated aldehydes. J. Appl. Toxicol. 2008, 28, 1027–1039. [Google Scholar] [CrossRef]
  41. Cee, V.J.; Volak, L.P.; Chen, Y.; Bartberger, M.D.; Tegley, C.; Arvedson, T.; McCarter, J.; Tasker, A.S.; Fotsch, C. Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution. J. Med. Chem. 2015, 58, 9171–9178. [Google Scholar] [CrossRef] [PubMed]
  42. Slawik, C.; Rickmeyer, C.; Brehm, M.; Böhme, A.; Schüürmann, G. Glutathione Adduct Patterns of Michael-Acceptor Carbonyls. Environ. Sci. Technol. 2017, 51, 4018–4026. [Google Scholar] [CrossRef]
  43. Neggers, J.; Vercruysse, T.; Jacquemyn, M.; Vanstreels, E.; Baloglu, E.; Shacham, S.; Crochiere, M.; Landesman, Y.; Daelemans, D. Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing. Chem. Biol. 2015, 22, 107–116. [Google Scholar] [CrossRef] [Green Version]
  44. Warshaviak, D.T.; Golan, G.; Borrelli, K.W.; Zhu, K.; Kalid, O. Structure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands. J. Chem. Inf. Model. 2014, 54, 1941–1950. [Google Scholar] [CrossRef]
  45. Zhu, K.; Borrelli, K.W.; Greenwood, J.R.; Day, T.; Abel, R.; Farid, R.S.; Harder, E. Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring. J. Chem. Inf. Model. 2014, 54, 1932–1940. [Google Scholar] [CrossRef] [PubMed]
  46. Devraj, R.; Kumaravel, G.; Lecci, C.; Loke, P.; Meniconi, M.; Monck, N.; North, C.; Ridgill, M.; Tye, H. Preparation of heteroaryl inhibitors of peptidylarginine deiminase 4. PCT Int. Appl. WO2018049296A1, 2018. [Google Scholar]
  47. Wang, K.-K.; Wang, P.; Ouyang, Q.; Du, W.; Chen, Y.-C. Substrate-controlled switchable asymmetric annulations to access polyheterocyclic skeletons. Chem. Commun. 2016, 52, 11104–11107. [Google Scholar] [CrossRef] [PubMed]
  48. Wang, W.; Zhang, Y.-W.; Hu, S.-J.; Niu, W.-P.; Zhang, G.-N.; Zhu, M.; Wang, M.-H.; Zhang, F.; Li, X.-M.; Wang, J.-X. Design, synthesis, and antibacterial evaluation of PFK-158 derivatives as potent agents against drug-resistant bacteria. Bioorg. Med. Chem. Lett. 2021, 41, 127980. [Google Scholar] [CrossRef]
  49. Parnell, K.M.; McCall, J.; Romero, D. Preparation of functionalized pyrazoles and other nitrogen-containing heterocycles as inhibitors of MCT4 for the treatment of MCT4-mediated diseases. U.S. Pat. Appl. Publ. US20180162822A1, 2018. [Google Scholar]
  50. Amslinger, S.; Al-Rifai, N.; Winter, K.; Wörmann, K.; Scholz, R.; Baumeister, P.; Wild, M. Reactivity assessment of chalcones by a kinetic thiol assay. Org. Biomol. Chem. 2013, 11, 549–554. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Berman, H.M.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef] [Green Version]
  52. Schrödinger Release 2018-3; Schrödinger, LLC: New York, NY, USA, 2018; Available online: https://www.schrodinger.com/citations (accessed on 13 October 2021).
  53. The PyMOL Molecular Graphics System; Version 2.0; Schrödinger, LLC: New York, NY, USA, 2017.
Pharmaceuticals 14 01131 g001 550
Figure 1. Chemical structures of several XPO1 inhibitors.
Figure 1. Chemical structures of several XPO1 inhibitors.
Pharmaceuticals 14 01131 g001
Pharmaceuticals 14 01131 g002 550
Figure 2. (A) Overall structure of the XPO1 protein (in deep purple), Ran (olive) and RanBP1 (sky blue). The NES-binding cleft is shown in grey. (B) Surface representation of the NES-binding cleft (grey) and the Φ0–Φ4 pockets. ScCys539 is shown in yellow and labelled. (C) Detailed view of KPT-8602 (yellow spheres, pdb id: 5jlj) inside of the NES-binding cleft.
Figure 2. (A) Overall structure of the XPO1 protein (in deep purple), Ran (olive) and RanBP1 (sky blue). The NES-binding cleft is shown in grey. (B) Surface representation of the NES-binding cleft (grey) and the Φ0–Φ4 pockets. ScCys539 is shown in yellow and labelled. (C) Detailed view of KPT-8602 (yellow spheres, pdb id: 5jlj) inside of the NES-binding cleft.
Pharmaceuticals 14 01131 g002
Pharmaceuticals 14 01131 g003 550
Figure 3. Chalcones synthesized and tested in this study as XPO1 inhibitors.
Figure 3. Chalcones synthesized and tested in this study as XPO1 inhibitors.
Pharmaceuticals 14 01131 g003
Pharmaceuticals 14 01131 sch001 550
Scheme 1. Reagents and conditions: (a) pyrimidine-5-carbaldehyde, Ba(OH)2, methanol/water, rt, 2 h, 55% yield; (b) as described in [28]: dimethyl carbonate, NaH, 1,4-dioxane, 70 °C, 3.5 h; (c) pyrimidine-5-carbaldehyde, piperidine, AcOH, 70–100 °C, 2–48 h, 30–40% yield; (d) NH3, 1,4-dioxane, 110 °C, 16 h, 34% yield; (e) as described in [30]: propionyl chloride, AlCl3, 1,2-DCE, rt, 16 h; (f) as described in [32]: acetonitrile, NaH, toluene, 110 °C, 16 h.
Scheme 1. Reagents and conditions: (a) pyrimidine-5-carbaldehyde, Ba(OH)2, methanol/water, rt, 2 h, 55% yield; (b) as described in [28]: dimethyl carbonate, NaH, 1,4-dioxane, 70 °C, 3.5 h; (c) pyrimidine-5-carbaldehyde, piperidine, AcOH, 70–100 °C, 2–48 h, 30–40% yield; (d) NH3, 1,4-dioxane, 110 °C, 16 h, 34% yield; (e) as described in [30]: propionyl chloride, AlCl3, 1,2-DCE, rt, 16 h; (f) as described in [32]: acetonitrile, NaH, toluene, 110 °C, 16 h.
Pharmaceuticals 14 01131 sch001
Pharmaceuticals 14 01131 sch002 550
Scheme 2. Reagents and conditions: (a) Ba(OH)2, methanol/water, rt, 2–7 h, 32–73% yield.
Scheme 2. Reagents and conditions: (a) Ba(OH)2, methanol/water, rt, 2–7 h, 32–73% yield.
Pharmaceuticals 14 01131 sch002
Pharmaceuticals 14 01131 sch003 550
Scheme 3. Reagents and conditions: (a) as described in [33]: MeI, Cs2CO3, DMF, 80 °C, 1 h; (b) pyrimidine-5-carbaldehyde, Ba(OH)2, methanol/water, rt, 16 h, 32–64% yield; (c) as described in [34]: dimethyl carbonate, NaH, 1,4-dioxane, 70 °C, 3 h; (d) pyrimidine-5-carbaldehyde, piperidine, AcOH, 70 °C, 16 h, 39% yield; (e) (i) as described in [35]: MeI, Cs2CO3, DMF, rt, 16 h, (ii) 2-bromoethylmethyl ether, Cs2CO3, DMF, 80 °C, 1 h, 77% yield; (f) (i) as described in [35]: MeI, Cs2CO3, DMF, rt, 16 h; (ii) 3,3-dimethylallyl bromide, Cs2CO3, DMF, 80 °C, 1 h, 75% yield.
Scheme 3. Reagents and conditions: (a) as described in [33]: MeI, Cs2CO3, DMF, 80 °C, 1 h; (b) pyrimidine-5-carbaldehyde, Ba(OH)2, methanol/water, rt, 16 h, 32–64% yield; (c) as described in [34]: dimethyl carbonate, NaH, 1,4-dioxane, 70 °C, 3 h; (d) pyrimidine-5-carbaldehyde, piperidine, AcOH, 70 °C, 16 h, 39% yield; (e) (i) as described in [35]: MeI, Cs2CO3, DMF, rt, 16 h, (ii) 2-bromoethylmethyl ether, Cs2CO3, DMF, 80 °C, 1 h, 77% yield; (f) (i) as described in [35]: MeI, Cs2CO3, DMF, rt, 16 h; (ii) 3,3-dimethylallyl bromide, Cs2CO3, DMF, 80 °C, 1 h, 75% yield.
Pharmaceuticals 14 01131 sch003
Pharmaceuticals 14 01131 g004 550
Figure 4. XPO1-mediated nuclear export of RanBP1 cargo protein. (A) Endogenous RanBP1 cargo protein (green) localized in the cytoplasm of untreated wild-type and mutant XPO1C528S Jurkat cells; (B) 3 h after treatment with 1 µM KPT-330 (Selinexor), RanBP1 accumulates in the nucleus of wild-type cells (left) but remains localized in the cytoplasm of mutant XPO1C528S cells (right); (C,D) 3 h after treatment with 4 µM of prototype compounds 9 or 10, respectively, nuclear accumulation of RanBP1 is found in wild-type Jurkat cells. In contrast, no nuclear retention of the cargo was induced in the mutant XPO1C528S cells. Scale bar 25 µm, and nuclei were counterstained with DAPI (blue).
Figure 4. XPO1-mediated nuclear export of RanBP1 cargo protein. (A) Endogenous RanBP1 cargo protein (green) localized in the cytoplasm of untreated wild-type and mutant XPO1C528S Jurkat cells; (B) 3 h after treatment with 1 µM KPT-330 (Selinexor), RanBP1 accumulates in the nucleus of wild-type cells (left) but remains localized in the cytoplasm of mutant XPO1C528S cells (right); (C,D) 3 h after treatment with 4 µM of prototype compounds 9 or 10, respectively, nuclear accumulation of RanBP1 is found in wild-type Jurkat cells. In contrast, no nuclear retention of the cargo was induced in the mutant XPO1C528S cells. Scale bar 25 µm, and nuclei were counterstained with DAPI (blue).
Pharmaceuticals 14 01131 g004
Pharmaceuticals 14 01131 g005 550
Figure 5. (A) Best CovDock solution of compound 9 (shown as purple sticks) at the NES-binding cleft of XPO1 (shown as light grey surface). (B) Best CovDock solution of compound 10 (shown as magenta sticks) at the NES-binding cleft of XPO1 (shown as light grey surface). Selected interacting residues from the NES-binding cleft are shown in green sticks and labeled, and hydrogen bond is shown as dashed lines.
Figure 5. (A) Best CovDock solution of compound 9 (shown as purple sticks) at the NES-binding cleft of XPO1 (shown as light grey surface). (B) Best CovDock solution of compound 10 (shown as magenta sticks) at the NES-binding cleft of XPO1 (shown as light grey surface). Selected interacting residues from the NES-binding cleft are shown in green sticks and labeled, and hydrogen bond is shown as dashed lines.
Pharmaceuticals 14 01131 g005
Table
Table 1. Antiproliferative activity of the synthesized chalcones against different tumor cell lines.
Table 1. Antiproliferative activity of the synthesized chalcones against different tumor cell lines.
IC50 (µM) a
CompHap-1 bHCT-116 bNCI-H460 bDND-41 bHL-60 bK-562 bZ-138 b
92.3 ± 0.22.4 ± 0.22.1 ± 0.12.1 ± 0.52.0 ± 0.51.8 ± 0.081.8 ± 0.05
102.1 ± 0.24.7 ± 1.73.5 ± 1.51.5 ± 0.22.2 ± 0.37.2 ± 1.90.5 ± 0.05
13≥54.9≥15.5≥47.1≥30.6>100>100>100
152.1 ± 0.75.3 ± 3.12.6 ± 0.78.9 ± 0.95.5 ± 3.62.1 ± 0.15.1 ± 2.7
18>100>100>10039.1 ± 5.3≥40.948.5 ± 2.4>100
241.6 ± 0.13.1 ± 0.94.3 ± 2.21.8 ± 0.53.5 ± 2.12.2 ± 0.031.6 ± 0.1
253.4 ± 0.53.9 ± 1.551.6 ± 11.72.6 ± 0.41.8 ± 0.054.8 ± 2.82.3 ± 0.5
262.3 ± 0.31.9 ± 0.47.7 ± 1.11.9 ± 0.40.9 ± 0.24.0 ± 0.21.1 ± 0.4
30≥32.0≥22.217.3 ± 4.643.2 ± 6.423.4 ± 1.942.9 ± 0.147.6 ± 1.1
334.3 ± 2.534.2 ± 6.516.9 ± 4.53.7 ± 1.610.0 ± 0.937.5 ± 0.91.5 ± 0.2
3410.0 ± 2.052.9 ± 3.634.5 ± 5.210.1 ± 0.040.2 ± 10.14.1 ± 1.94.6 ± 2.7
KPT-3300.07 ± 0.030.10 ± 0.10.12 ± 0.080.05 ± 0.00.11 ± 0.10.09 ± 0.00.40 ± 0.4
a IC50: concentration of compound at which 50% of cell proliferation is inhibited. Mean value of two independent experiments ±SEM. b Hap-1: chronic myeloid leukemia; HCT-116: colorectal carcinoma; NCI-H460: lung carcinoma; DND-41: acute lymphoblastic leukemia; HL-60: acute myeloid leukemia; K-562: chronic myeloid leukemia; Z-138: non-Hodgkin lymphoma.
Table
Table 2. XPO1 inhibition.
Table 2. XPO1 inhibition.
CompIC50 (µM) a
92.46 ± 0.16
100.55 ± 0.19
13>100
59.18 ± 3.28
18>100
241.27 ± 0.29
257.28 ± 1.34
2610.74 ± 3.24
3087.34 ± 4.91
3312.35 ± 1.28
341.59 ± 0.36
KPT-3300.05
a IC50 (50% inhibitory concentration) is given as the mean ± SEM of two independent experiments.
Table
Table 3. IC50 values of 9 and 10 in means of XPO1 inhibition in wild-type and XPO1C528S mutant Jurkat cell lines.
Table 3. IC50 values of 9 and 10 in means of XPO1 inhibition in wild-type and XPO1C528S mutant Jurkat cell lines.
CompIC50 (μM) a
Jurkat XPO1WTJurkat XPO1C528S
KPT-3300.07 ± 0.01>5
92.2 ± 0.03>5
100.3 ± 0.3>5
a IC50 (50% inhibitory concentration) is given as the mean ±SD of two independent experiments.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Gargantilla, M.; López-Fernández, J.; Camarasa, M.-J.; Persoons, L.; Daelemans, D.; Priego, E.-M.; Pérez-Pérez, M.-J. Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones. Pharmaceuticals 2021, 14, 1131. https://doi.org/10.3390/ph14111131

AMA Style

Gargantilla M, López-Fernández J, Camarasa M-J, Persoons L, Daelemans D, Priego E-M, Pérez-Pérez M-J. Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones. Pharmaceuticals. 2021; 14(11):1131. https://doi.org/10.3390/ph14111131

Chicago/Turabian Style

Gargantilla, Marta, José López-Fernández, Maria-Jose Camarasa, Leentje Persoons, Dirk Daelemans, Eva-Maria Priego, and María-Jesús Pérez-Pérez. 2021. "Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones" Pharmaceuticals 14, no. 11: 1131. https://doi.org/10.3390/ph14111131

APA Style

Gargantilla, M., López-Fernández, J., Camarasa, M. -J., Persoons, L., Daelemans, D., Priego, E. -M., & Pérez-Pérez, M. -J. (2021). Inhibition of XPO-1 Mediated Nuclear Export through the Michael-Acceptor Character of Chalcones. Pharmaceuticals, 14(11), 1131. https://doi.org/10.3390/ph14111131

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop